成都婴儿血管瘤手术大约要费用(成都哪个医院冶静脉曲张) (今日更新中)

WASHINGTON, March 24 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Thursday approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older.In the United States shingles affects approximately 200,000 healthy people between the ages of 50 and 59, per year. It is a disease caused by the varicella-zoster virus, which is a virus in the herpes family and the same virus that causes chickenpox.After an attack of chickenpox, the virus lies dormant in certain nerves in the body. For reasons that are not fully understood, the virus can reappear in the form of shingles, more commonly in people with weakened immune systems and with aging."The likelihood of shingles increases with age. The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease" said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement. ( Shingles is characterized by a rash of blisters, which generally develop in a band on one side of the body and can cause severe pain that may last for weeks, and in some people, for months or years after the episode.Approval was based on a multicenter study conducted in the United States and four other countries in approximately 22,000 people who were 50-59 years of age. Half received Zostavax and half received a placebo. Study participants were then monitored for at least one year to see if they developed shingles. Compared with placebo, Zostavax reduced the risk of developing shingles by approximately 70 percent.The most common side effects observed in the study were redness, pain and swelling at the site of injection, and headache, according to the FDA.Zostavax, manufactured by Merck & Co., was originally approved on May 26, 2006, for the prevention of shingles in individuals 60 years of age and older.

TIANJIN, April 16 (Xinhua) -- As China tries to establish a universal medicare umbrella, its first move to offer treatment to all the hemophilia patients in the country is to know their population and where they are.China's national hemophilia information management center registered 7,980 cases nationwide since its establishment last year in a bid to provide reference for making national treatment policies and medicine production quota, said the center officials Saturday.Yang Renchi with the center and the Chinese Academy of Medical Sciences, said that the patient information database will help the government make hemophilia-related medical and social welfare policies, optimize resources and guide the manufacturing of drugs such as coagulation factor VIII.The information center, created by the Ministry of Health, is located in the Blood Diseases Hospital of the Chinese Academy of Medical Sciences in the port city Tianjin in north China.Hemophilia is a rare genetic bleeding disorder that prevents the blood from clotting properly, resulting in easy bruising and prolonged bleeding from trauma. Lack of treatment can lead to permanent disabilities or even death.China is estimated to have roughly 100,000 hemophilia patients."Be inspired; get involved in Treatment for All" is the theme for the 22nd World Hemophilia Day, which falls on Sunday, April 17."A necessary precondition for 'Treatment for All' is to know the clinical information and location of each case," said Yang, "and this is exactly what the information system does."In addition, China plans to establish hospital-based provincial hemophilia management centers within five years across the country to register and monitor patients and standardize disease diagnosis and treatment under the information system.SHORTAGE OF DRUGSBlood-derived coagulation factor VIII and recombinant coagulation factor VIII are two effective drugs which are vital for hemophiliacs. However, the drugs are expensive and produced in limited quantities, a difficulty which hundreds of thousands of hemophiliacs in China have to confront.According to Yang, the minimum dose of coagulation factor VIII for prevention of bleeding episodes is two international units (IU) per kg of weight a day. A 50-kg hemophilia patient needs at least 36,500 IU of factor VIII every year to prevent bleeding."Each IU of blood-derived coagulation factor VIII costs about 3 yuan(0.46 U.S. dollars) and the annual cost is almost 120,000 yuan. The recombinant one is almost twice the price," said Yang.Only four drug firms are qualified to manufacture blood-derived coagulation factor VIII in China. The national output in 2010 was 400,000 vials (200 IU per vial) which means 80 million IU for the entire country.Wu Runhui, a hematology specialist with the Beijing Children's Hospital, said that the minimum dose is only for the prevention of bleeding episodes which are required to keep the patient alive. For the hemophiliac to live a regular lifestyle, 3,000 IU per kilo a year is needed, which would cost half a million yuan a year."Even in the most developed countries, a hemophiliac cannot survive without supportive medical policies and social welfare system," said Wu.

BEIJING, Feb. 24 (Xinhua) -- The Standing Committee of the National People's Congress (NPC) will vote on draft laws on vehicle and boat taxes at the end of its bimonthly sessions on Friday.The group is also expected to vote on protecting the nation's intangible cultural heritage and a draft amendment to the Criminal Law.The Chairperson's Council of the NPC Standing Committee adopted the decision at a Thursday meeting presided over by NPC Standing Committee Chairman Wu Bangguo.The three drafts will undergo further deliberation and revision based upon the opinion of the members of the NPC Standing Committee before the laws are put to a vote.Under the draft law on vehicle and vessel taxes, there will be a reduction in taxes for vehicles with engines smaller than 2.0 liters, which accounts for 87 percent of China's cars. Vehicle owners would also be required to submit tax certificates in order to qualify for a road-worthiness certificate.

STOCKHOLM, Jan. 26 (Xinhua) -- China's railway network, already the world's longest, is developing at record high speed and is to be doubled soon, Swedish daily Svenska Dagbladet reported on Wednesday."China's goal is to connect all important cities with railway lines," the report said.Collaborating with German Siemens, Japanese Kawasaki and Bombardier both in Canada and Sweden, China has built its own high-speed train CRH380A that can reach 486 kilometers per hour, cutting the journey between Beijing and Shanghai in half to about 4 hours.Construction of the high-speed railway network will also cover inland China, the report said. It aims to encourage more investment to move from coastal areas to inland China and ultimately raise the living standards in those regions.Within the next five years, a total of 3.5 trillion yuan (over 500 billion U.S. dollars) will be invested in high-speed track construction and train manufacturing, averaging at about 700 billion yuan (over 100 billion dollars) each year.Swedish companies such as Atlas Copco, SKF and Trelleborg have participated in China's railway and high-speed train development, according to the report.Hans Rosling, a development expert and also professor at Karolinska Institutet in Sweden, was quoted as saying that the construction of the high-speed railway network will bring about "good economy, good education, good medical care, better and longer life, all good things."

来源：资阳报